CN113429440A - Prodrug of spiro compound, preparation method and application thereof in medicine - Google Patents
Prodrug of spiro compound, preparation method and application thereof in medicine Download PDFInfo
- Publication number
- CN113429440A CN113429440A CN202110305777.9A CN202110305777A CN113429440A CN 113429440 A CN113429440 A CN 113429440A CN 202110305777 A CN202110305777 A CN 202110305777A CN 113429440 A CN113429440 A CN 113429440A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- compound
- cancer
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000651 prodrug Substances 0.000 title claims abstract description 48
- 229940002612 prodrug Drugs 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 150000003413 spiro compounds Chemical class 0.000 title abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 79
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims description 137
- -1 cyano, amino Chemical group 0.000 claims description 123
- 125000000623 heterocyclic group Chemical group 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 74
- 125000001072 heteroaryl group Chemical group 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 61
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 49
- 239000012453 solvate Substances 0.000 claims description 47
- 125000001188 haloalkyl group Chemical group 0.000 claims description 39
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 37
- 150000002367 halogens Chemical class 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 35
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 32
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010027406 Mesothelioma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 8
- 206010042863 synovial sarcoma Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 230000002018 overexpression Effects 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 238000004949 mass spectrometry Methods 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 21
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 125000006413 ring segment Chemical group 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 16
- 102000020233 phosphotransferase Human genes 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 125000003282 alkyl amino group Chemical group 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 description 10
- 125000005366 cycloalkylthio group Chemical group 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 238000004293 19F NMR spectroscopy Methods 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 102000001253 Protein Kinase Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 6
- 238000004679 31P NMR spectroscopy Methods 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 3
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HPNBWHDRLCVZFV-UHFFFAOYSA-N 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound CC1=CC=C(N)C=C1B1OC(C)(C)C(C)(C)O1 HPNBWHDRLCVZFV-UHFFFAOYSA-N 0.000 description 2
- OWVCAVCZOSBFBJ-UHFFFAOYSA-N 5-(trifluoromethyl)pyridazine-3-carboxylic acid Chemical compound OC(=O)c1cc(cnn1)C(F)(F)F OWVCAVCZOSBFBJ-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- JWMLCCRPDOIBAV-UHFFFAOYSA-N chloro(methylsulfanyl)methane Chemical compound CSCCl JWMLCCRPDOIBAV-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000004468 heterocyclylthio group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
- LQCMMXGKEGWUIM-UHFFFAOYSA-N 1-(4-bromo-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1O LQCMMXGKEGWUIM-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical compound N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 1
- PFWKHMUYGITBLO-UHFFFAOYSA-N 7-bromospiro[3h-chromene-2,4'-oxane]-4-one Chemical compound O1C2=CC(Br)=CC=C2C(=O)CC21CCOCC2 PFWKHMUYGITBLO-UHFFFAOYSA-N 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CXIATFKTZDMDQL-PYCFMQQDSA-N CC(C=C1)=CC=C1S(O/N=C(/CC1(CCOCC1)OC1=C2)\C1=CC=C2Br)(=O)=O Chemical compound CC(C=C1)=CC=C1S(O/N=C(/CC1(CCOCC1)OC1=C2)\C1=CC=C2Br)(=O)=O CXIATFKTZDMDQL-PYCFMQQDSA-N 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 102000042888 RAF family Human genes 0.000 description 1
- 108091082327 RAF family Proteins 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003921 pyrrolotriazines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to prodrugs of spiro compounds, methods of preparation thereof, and pharmaceutical uses thereof. Specifically, the disclosure relates to a prodrug of a spiro compound represented by general formula (I), a preparation method thereof, a prodrug-containing composition, and use thereof as a therapeutic agent, in particular use thereof as a RAF inhibitor and use thereof for preparing a medicament for treating or preventing various diseases (including cancer) associated with over-expression RAF activity.
Description
Technical Field
The present disclosure relates to prodrugs of spiro compounds having biological activity, pharmaceutical compositions comprising the prodrugs, intermediates, and synthetic methods for preparing the prodrugs, as well as uses of the prodrugs and compositions thereof in treating or preventing various diseases, particularly diseases associated with RAF overexpression activities, such as cancer.
Background
The receptor tyrosine kinase RAF, also known as rapid accelerated fibrosarcoma, is a family of serine/threonine specific protein kinases. There are three known mammalian subtypes of RAF: A. b and C-Raf (also called Raf-1). RAF kinases participate in the RAS-RAF-MEK-ERK signal transduction reaction in Mitotically Activated Protein Kinase (MAPK) cascades (Moelling K, et al, Nature.1984.312(5994): 558-61.). The Ras-Raf-MAPK channel controls various cellular physiological processes. Extensive studies have shown that RAF family kinases play a key role in regulating Cell survival, proliferation, differentiation, apoptosis and many other physiological processes through MAPK cascades (Lavoie H et al Nat Rev Mol Cell biol.2015 (5): 281-98.). Abnormalities of the Ras-Raf-MAPK channel are implicated in a variety of biological processes associated with human disease. Excessive activity of the Ras-Raf-MAPK channel component is a common mechanism of proliferative diseases (e.g., cancer) (Leicht DT, et al. Biochim Biophys acta.2007,1773(8): 1196-212.).
In view of the close correlation between RAF activity and cancer, RAF has been used as a target for drug discovery in cancer therapy and the like. Many ATP-competitive RAF inhibitors (PLX4032/Vemurafenib, Dabrafenib, Sorafenib, etc.) have been approved for the treatment of metastatic melanoma patients and have been shown to have a positive clinical efficacy in melanoma with a relapse allele of BRAFV600E (Holderfield, m., et al. nat Rev cancer.2014,14(7): 455-67). Unfortunately, resistance to these drugs is always partially acquired by mechanisms that stimulate RAF dimerization. Therefore, if a next generation RAF inhibitor could be developed to be effective against tumors carrying the BRAFV600E mutation as well as wild-type BRAF or RAS mutations, there would be a tremendous clinical outcome. See, e.g., Allgeier, m.c. et al, WO2013/134243 filed 3, 5.2013; US2014/0275003 filed on 11/3/2014 by Batsanti, p.a. et al. In some cases, it may be desirable to improve its solubility or other properties, such as its bioavailability, by a particular route of administration.
A prodrug is a drug or compound that is metabolized to a pharmacologically active drug after administration. While prodrugs can be metabolized to the active form (prodrug) in vivo, prodrugs are generally pharmacologically inactive. Prodrugs employ various physical and chemical modifications to improve the function of the active drug. Instead of directly administering the prodrug, the corresponding prodrug can be used to improve ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. Prodrugs are often designed to enhance the bioavailability of a drug when the drug itself is poorly absorbed in the body. Prodrugs can be used to improve drug selectivity or to avoid off-target effects. To reduce adverse or accidental reactions of the drug. In certain treatments, such as chemotherapy, which may have serious unexpected and undesirable side effects, the use of prodrug strategies to improve patient compliance is of great interest.
There are some published FDA-approved phosphate prodrugs on the market, such as fospinytin (i) and fostamatinib (ii).
In WO 2017/070135, published on 27.4.2017, Purandare, a.v., a prodrug of imidazotriazine (iii) is disclosed as CK2 protein kinase inhibitor for the treatment of cancer.
In US 2007/0213300 published on 13.9.2007, Liu, c. discloses prodrugs of pyrrolotriazines (iv) to treat diseases associated with p38 kinase.
In WO 2014/198647, published 12/18/2014, Schulze, v, discloses prodrugs (v) of triazolopyridines as Mps-1 kinase inhibitors and their use in the treatment of proliferative diseases.
A number of prodrug strategies exist that can provide different conditions to modulate the following properties: the resulting release of the prodrug, the physical, pharmaceutical or pharmacokinetic properties of the prodrug, and the site of attachment of functional groups that can be used for modification of the prodrug. However, the prior art does not teach or suggest specific prodrugs of the present disclosure. Finding and identifying prodrugs with desirable properties is often difficult and tortuous.
Disclosure of Invention
In one aspect of the present disclosure, there is provided a compound of formula (I),
or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,
wherein:
G1selected from O, S, C (═ O), C (═ O) NH and NR6、CR7R8And S (═ O)2;
Ring a is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
X1and X2Are the same or different and are each independently a hydrogen atom or L-R0(ii) a Provided that X is1And X2Not being hydrogen atoms at the same time;
l is selected from-CH2-、-C(=O)O(CQ1Q2)n-and-C (═ O) S (CQ)1Q2)n-;
R0Selected from-OP (═ O) (OH)2、-OP(=O)(OH)-OP(=O)(OH)2、-OC(=O)Q3、-OC(=O)OQ3、-OC(=O)NHQ3、-OP(=O)(OQ4)2、-O-C(=O)(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)(CQ1Q2)n-Cy-OP(=O)(OH)2、-OC(=O)CH=CHC(=O)OH、-O-C(=O)-O-(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)-NH-(CQ1Q2)n-OP(=O)(OH)2、-OC(=O)CH(Q5)-NQ6Q7and-NQ6Q7;
Cy is aryl or heteroaryl, each independently optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
Q1、Q2、Q3and Q5Are identical or different and are each independently selected from the group consisting of a hydrogen atom, an alkyl group and-C (═ O) R9Wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
Q4selected from alkyl, -CH2OC(=O)R9and-CH2-OC(=O)OR9;
Q6And Q7Are identical or different and are each independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, -C (═ O) R9Cycloalkyl, heterocyclyl, aryl and heteroaryl;
R1are the same or different and are each independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, carboxyl, amino, or amino, or amino, or amino, or amino, or amino, or amino, or amino, or amino, or amino,Nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl, each of which is independently optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R2aand R2The same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R3the same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R4and R5The same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R6selected from the group consisting of hydrogen atom, alkyl group, haloalkyl group, hydroxyl group, hydroxyalkyl group, amino group, cycloalkyl group, heterocyclic group, C (O) OR10、C(O)R11Aryl and heteroaryl;
R7and R8Are the same OR different and are each independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, C (O) OR10Aryl and heteroaryl;
or R7And R8Together form a cycloalkyl or heterocyclyl group;
R9is alkyl, optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkoxy, hydroxy, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R10selected from hydrogenAtoms, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R11selected from the group consisting of hydrogen atoms, alkyl groups, haloalkyl groups, hydroxyalkyl groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups;
n is an integer of 1 to 6;
r is 0, 1,2 or 3;
s is 0, 1,2, 3 or 4; and is
q is 0, 1,2, 3 or 4.
In some embodiments of the present disclosure, a compound of formula (I), or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein G is1Is an O atom.
In some embodiments of the present disclosure, a compound of formula (I), or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein R is2aIs C1-6Alkyl, preferably methyl.
In some embodiments of the present disclosure, a compound of formula (I), or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein R is4And R5Is a hydrogen atom.
In some embodiments of the present disclosure, a compound of formula (I), which is a compound of formula (II) or formula (III), or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,
wherein:
ring A, X1、X2、R1、R2、R3S, r and q are as defined in formula (I).
In some embodiments of the present disclosure, the compounds of formula (I) and formula (II), or tautomers, cis-or trans-isomers, meso-isomers, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein X is1And X2Are the same or different and are each independently selected from the group consisting of a hydrogen atom, -CH2-R0and-C (═ O) O (CQ)1Q2)n-R0(ii) a Provided that X is1And X2Not being hydrogen atoms at the same time; r0、Q1、Q2And n is as defined in formula (I).
In some embodiments of the present disclosure, the compounds of formula (I) and formula (II), or tautomers, cis-or trans-isomers, meso-isomers, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein X is1And X2Are the same or different and are each independently selected from the group consisting of a hydrogen atom, -CH2OC(=O)CH3、-CH2OC(=O)OCH3、-CH2OC(=O)NHCH3、-CH2OP(=O)(OH)2、-CH2OP(=O)(OH)OP(=O)(OH)2、-CH2OP(=O)(OQ4)2、-C(=O)OCH2OC(=O)C(CH3)3、-C(=O)OCH2OP(=O)(OH)2、-C(=O)OCH2CH2OP(=O)(OH)2、-C(=O)OCH2OC(=O)CH=CHCOOH、 Provided that X is1And X2Is not simultaneousIs a hydrogen atom; q4As defined in formula (I); preferably, X1is-CH2OP(=O)(OH)2(ii) a And X2Is a hydrogen atom; or, X1Is a hydrogen atom; and X2is-CH2OP(=O)(OH)2。
In some embodiments of the present disclosure, the compounds of formula (I) and formula (II), which are compounds of formula (III) or formula (IV), or tautomers, cis or trans isomers, meso forms, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof,
wherein:
L1and L2Are the same or different and are each independently selected from-CH2-、-C(=O)O(CQ1Q2)n-and-C (═ O) S (CQ)1Q2)n-; preferably, L1And L2Are the same or different and are each independently-CH2-;
RaAnd RbAre identical or different and are each independently selected from the group consisting of-OP (═ O) (OH)2、-OP(=O)(OH)-OP(=O)(OH)2、-OC(=O)Q3、-OC(=O)OQ3、-OC(=O)NHQ3、-OP(=O)(OQ4)2、-O-C(=O)(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)(CQ1Q2)n-Cy-OP(=O)(OH)2,-OC(=O)CH=CHC(=O)OH、-O-C(=O)-O-(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)-NH-(CQ1Q2)n-OP(=O)(OH)2、-OC(=O)CH(Q5)-NQ6Q7and-NQ6Q7(ii) a preferably-OP (═ O) (OH)2。
Ring A, R1、R2、R3、Cy、Q1~Q7S, r, q and n are as defined in formula (I).
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III), and formula (IV), or tautomers, cis or trans isomers, meso, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein ring a is a 5-or 6-membered heteroaryl; pyridyl, pyridazinyl and pyrimidinyl are preferred.
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III) and formula (IV), or tautomers, cis or trans isomers, meso, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, whereinSelected from: R1and s is as defined in formula (I).
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III) and formula (IV), or tautomers, cis or trans isomers, meso forms, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein R is1Selected from the group consisting of hydrogen atoms, haloalkyl groups and haloalkoxy groups; preferably selected from hydrogen atoms, halogenated C1-6Alkyl or halo C1-6An alkoxy group.
In some embodiments of the disclosure, the compounds of formula (I), formula (II), formula (III), and formula (IV), or tautomers, cis or trans isomers, meso, racemates, enantiomers, diastereomers, or mixtures thereofA form of matter, or a pharmaceutically acceptable salt or solvate thereof, wherein R1Is haloalkyl or haloalkoxy; preferably a halogen atom1-6Alkyl or halo C1-6An alkoxy group.
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III) and formula (IV), or tautomers, cis or trans isomers, meso forms, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein R is2And R3Is a hydrogen atom.
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III), and formula (IV), or tautomers, cis or trans isomers, meso, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein s is 0 or 1.
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III), and formula (IV), or tautomers, cis or trans isomers, meso, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein q is 0 or 1.
In some embodiments of the present disclosure, the compounds of formula (I), formula (II), formula (III), and formula (IV), or tautomers, cis or trans isomers, meso forms, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, wherein r is 0 or 1.
In some embodiments of the present disclosure, a compound of formula (II), or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, whereinSelected from: R1selected from the group consisting of hydrogen atoms, haloalkyl groups and haloalkoxy groups; preferably selected from hydrogen atoms, halogenated C1-6Alkyl or halo C1-6An alkoxy group; x1is-CH2OP(=O)(OH)2(ii) a And X2Is a hydrogen atom; or, X1Is a hydrogen atom; and X2is-CH2OP(=O)(OH)2;R2And R3Is a hydrogen atom; s is 0 or 1.
Table a exemplary prodrug compounds of the present disclosure include, but are not limited to:
other exemplary prodrug compounds of the present disclosure include, but are not limited to:
In another aspect of the present disclosure, there is provided a compound represented by formula (IIIA) or (IVA):
or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein:
Rwis-SCH3Or an iodine atom;
ring a is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
L1and L2Are the same or different and are each independently selected from-CH2-、-C(=O)O(CQ1Q2)n-and-C (═ O) S (CQ)1Q2)n-; preferably, L1And L2Are the same or different and are each independently-CH2-;
Q1And Q2Are identical or different and are each independently selected from the group consisting of a hydrogen atom, an alkyl group and-C (═ O) R9Wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R9is alkyl, optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkoxy, hydroxy, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R1the same or different, and each is independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently selected from the group consisting ofOptionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R2the same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R3the same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
n is an integer of 1 to 6;
r is 0, 1,2 or 3;
s is 0, 1,2, 3 or 4; and is
q is 0, 1,2, 3 or 4. Which is an intermediate for the preparation of formula (III) or formula (IV).
Exemplary intermediates of the present disclosure include, but are not limited to:
in another aspect of the present disclosure, there is provided a process for preparing a prodrug compound of formula (III) or formula (IV), or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, the process comprising:
formula (IIIA) formulaCompound and Ra-H reaction to give a compound of general formula (III);
compounds of the general formula (IVA) and Rb-H reaction to give a compound of general formula (IV);
wherein:
Rwis-SCH3;
Ring A, R1、R2、R3、L1、L2、Ra、RbS, r and q are as defined for compounds of formula (III) or formula (IV).
The present disclosure provides a pharmaceutical composition comprising a compound of formula (I), formula (II), formula (III), formula (IV) and table a, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
The present disclosure provides for the use of a compound of formula (I), formula (II), formula (III), formula (IV) and shown in table a, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for inhibiting RAF.
The present disclosure provides the use of a compound of formula (I), formula (II), formula (III), formula (IV) and shown in table a, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for the treatment of a RAF mediated disease or disorder. Preferably, the RAF mediated disease or disorder is a tumor, more preferably, the RAF mediated disease or disorder is cancer. Wherein the tumor (preferably cancer) is selected from the group consisting of lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, mesothelioma, cervical cancer, colon cancer, rectal cancer, stomach cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, bone cancer, kidney cancer, bladder cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, glioma, glioblastoma, head and neck cancer, and myeloma; lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, and mesothelioma are preferred.
The present disclosure provides a method of inhibiting RAF comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), formula (II), formula (III), formula (IV) and table a or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same.
The present disclosure provides a method of treating a RAF mediated disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), formula (II), formula (III), formula (IV) and table a or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same. Preferably, the RAF mediated disease or disorder is a tumor, more preferably, the RAF mediated disease or disorder is cancer. Wherein the tumor (preferably cancer) is selected from the group consisting of lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, mesothelioma, cervical cancer, colon cancer, rectal cancer, stomach cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, bone cancer, kidney cancer, bladder cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, glioma, glioblastoma, head and neck cancer, and myeloma; lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, and mesothelioma are preferred.
Another aspect of the present disclosure provides a compound of formula (I), formula (II), formula (III), formula (IV) and table a or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same, for use as a medicament.
Another aspect of the present disclosure provides a compound of formula (I), formula (II), formula (III), formula (IV) and table a or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same, for use as a medicament for inhibiting RAF.
Another aspect of the present disclosure provides a compound of formula (I), formula (II), formula (III), formula (IV) and table a or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same, for use in the treatment of a RAF mediated disease or disorder. Preferably, the RAF mediated disease or disorder is a tumor, more preferably, the RAF mediated disease or disorder is cancer. Wherein the tumor (preferably cancer) is selected from the group consisting of lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, mesothelioma, cervical cancer, colon cancer, rectal cancer, stomach cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, bone cancer, kidney cancer, bladder cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, glioma, glioblastoma, head and neck cancer, and myeloma; lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, and mesothelioma are preferred.
The tumors occurring in the above cancers are malignant tumors.
The active compounds may be formulated in a form suitable for administration by any suitable route, using one or more pharmaceutically acceptable carriers to formulate compositions of the invention by conventional means. Thus, the active compounds of the present invention may be formulated in a variety of dosage forms for oral administration, injection (e.g., intravenous, intramuscular, or subcutaneous), inhalation, or insufflation. The compounds of the present invention may also be formulated in sustained release dosage forms, such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges or syrups.
The dosage of the compound or composition used in the methods of treatment of the present invention will generally vary with the severity of the disease, the weight of the patient and the relative efficacy of the compound. However, as a general guide, the active compound is preferably in unit dosage form, or in such a way that the patient can self-administer it in a single dose. The unit dose of a compound or composition of the invention may be expressed in the form of a tablet, capsule, cachet, bottle, powder, granule, lozenge, suppository, reconstituted powder or liquid. A suitable unit dose may be 0.1 to 1000 mg.
The pharmaceutical compositions of the invention may contain, in addition to the active compound, one or more adjuvants selected from the following: fillers (diluents), binders, wetting agents, disintegrants, excipients, and the like. Depending on the method of administration, the compositions may contain from 0.1 to 99% by weight of active compound.
Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be inert excipients, granulating agents, disintegrating agents, binding agents and lubricating agents. These tablets may be uncoated or they may be coated by known techniques which mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
Oral formulations may also be provided in soft gelatin capsules wherein the active ingredient is mixed with an inert solid diluent or wherein the active ingredient is mixed with a water soluble carrier or an oil vehicle.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending, dispersing or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents.
Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, or in a mineral oil. The oil suspension may contain a thickener. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable preparation. These compositions can be preserved by the addition of antioxidants.
The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, or a mineral oil or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsions may also contain sweetening, flavoring, preservative and antioxidant agents. Such formulations may also contain a demulcent, a preservative, a colorant and an antioxidant.
The pharmaceutical compositions of the present disclosure may be in the form of a sterile injectable aqueous solution. Among the acceptable vehicles or solvents that may be employed are water, ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase, and the injection or microemulsion may be injected into the bloodstream of a patient by local mass injection. Alternatively, it may be desirable to administer the solution and microemulsion in a manner that maintains a constant circulating concentration of the disclosed compounds. To maintain such a constant concentration, a continuous intravenous delivery device may be used. An example of such a device is an intravenous pump model Deltec CADD-PLUS. TM.5400.
The pharmaceutical compositions of the present disclosure may be in the form of sterile injectable aqueous or oleaginous suspensions for intramuscular and subcutaneous administration. The suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally-acceptable, non-toxic diluent or solvent. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any blend fixed oil may be used for this purpose. In addition, fatty acids can also be prepared into injections.
The compounds of the present disclosure may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and therefore will melt in the rectum to release the drug.
Dispersible powders and granules of the compounds of the present disclosure can be administered by the addition of water to prepare an aqueous suspension. These pharmaceutical compositions may be prepared by mixing the active ingredient with dispersing or wetting agents, suspending agents, or one or more preservatives.
As is well known to those skilled in the art, the dosage of a drug administered depends on a variety of factors, including, but not limited to: the activity of the particular compound employed, the age of the patient, the weight of the patient, the health condition of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, and the like; in addition, the optimal treatment regimen, such as mode of treatment, daily amount of compound or type of pharmaceutically acceptable salt, can be verified according to conventional treatment protocols.
Term part
Unless stated to the contrary, terms used in the specification and claims have the following meanings.
The term "alkyl" refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 (e.g., 1,2, 3, 4,5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably a lower alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-dimethylpentyl, 2, 4-dimethylpentyl, 2-dimethylpentyl, 3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2, 3-dimethylhexyl, 2, 4-dimethylhexyl, 2, 5-dimethylhexyl, 2-dimethylhexyl, 3-dimethylhexyl, 4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2-dimethylpentyl, 2-dimethylhexyl, 3-dimethylpentyl, 2-ethylhexyl, 3-dimethylhexyl, 2-ethylhexyl, 2-dimethylhexyl, 2-ethylhexyl, 2-dimethylhexyl, 2-dimethylhexyl, 2-dimethylhexyl, 2-ethylhexyl, 2-ethyl, 2-2, 2-2, 2-2, or, 2, 2-diethylpentyl, n-decyl, 3-diethylhexyl, 2-diethylhexyl, and various branched isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl and the like. The alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more groups independently selected from halogen, alkoxy, alkenyl, alkynyl, alkylthio, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycle, cycloalkylthio, heterocyclylthio, and oxo.
The term "alkenyl" refers to an alkyl compound containing a carbon-carbon double bond in the molecule, wherein alkyl is as defined above. For example, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-or 3-butenyl, and the like. Preferably 2 to 20 carbon atoms, more preferably 2 to 12 (e.g., 2,3, 4,5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, most preferably 2 to 6 carbon atoms, and the like. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from halogen, alkoxy, alkynyl, alkylthio, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycle, cycloalkylthio, heterocyclylthio, and oxo.
The term "alkynyl" refers to an alkyl compound containing a carbon-carbon triple bond in the molecule, wherein alkyl is as defined above. For example, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-or 3-butynyl and the like. Preferably 2 to 20 carbon atoms, more preferably 2 to 12 (e.g. 2,3, 4,5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, most preferably 2 to 6 carbon atoms. Alkynyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkenyl, alkoxy, alkylthio, alkylamino, halo, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycle, alkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.
The term "alkylene" refers to a saturated straight or branched aliphatic hydrocarbon group, which is a residue derived from the parent alkane by removal of two hydrogen atoms from the same carbon atom or two different carbon atoms, and is a straight or branched group containing from 1 to 20 carbon atoms, preferably from 1 to 12 (e.g., 1,2, 3, 4,5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably from 1 to 6 carbon atoms. Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH)2-), 1-ethylidene (-CH (CH)3) -), 1, 2-ethylene (-CH)2CH2) -, 1-propylene (-CH (CH)2CH3) -), 1, 2-propylene (-CH)2CH(CH3) -), 1, 3-propylene (-CH)2CH2CH2-) 1, 4-butylene (-CH2CH2CH2CH2-) and the like. The alkylene group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more independently selected from the group consisting of alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio and heterocycloalkylthio.
The term "alkenylene" refers to an alkylene compound containing a carbon-carbon double bond in the molecule, wherein the alkylene isThe radicals are as defined above. Preferably 2 to 20 carbon atoms, more preferably 2 to 12 (e.g. 2,3, 4,5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, most preferably 2 to 6 carbon atoms. Non-limiting examples of alkenylene include, but are not limited to, ethenylene (-CH-), propenylene (-CH-CHCH)2-, 1-butenylene (-CH ═ CHCH)2CH2-, 2-butenylene (-CH)2CH=CHCH2-) and the like. Alkenylene may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.
The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing from 3 to 20 carbon atoms, preferably 3 to 12 (e.g., 3, 4,5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms (e.g., 3, 4,5, 6, 7, or 8) or 3 to 6 (3, 4,5, or 6) carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like. Polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups.
The term "spirocycloalkyl" refers to a5 to 20 membered polycyclic group sharing one carbon atom (referred to as a spiro atom) between single rings, which may contain one or more double bonds. Preferably 6 to 14, more preferably 7 to 10 (e.g. 7, 8, 9 or 10). Spirocycloalkyl groups are classified into a single spirocycloalkyl group, a double spirocycloalkyl group or a multi spirocycloalkyl group, preferably a single spirocycloalkyl group and a double spirocycloalkyl group, according to the number of spiro atoms shared between rings. More preferably 3-membered/5-membered, 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered, spirocycloalkyl. Non-limiting examples of spirocycloalkyl groups include:
the term "fused cyclic alkyl" refers to a5 to 20 membered all carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more double bonds. Preferably 6 to 14, more preferably 7 to 10 (e.g. 7, 8, 9 or 10). They may be classified into bicyclic, tricyclic, tetracyclic or polycyclic fused ring alkyls according to the number of constituent rings, preferably bicyclic or tricyclic, more preferably 5-or 6-membered bicycloalkyl. Non-limiting examples of fused ring alkyl groups include:
the term "bridged cycloalkyl" refers to a5 to 20 membered all carbon polycyclic group in which any two rings share two carbon atoms not directly attached, which may contain one or more double bonds. Preferably 6 to 14, more preferably 7 to 10 (e.g. 7, 8, 9 or 10). They may be classified as bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic, depending on the number of constituent rings. Non-limiting examples of bridged cycloalkyl groups include:
such cycloalkyl rings include those wherein the above cycloalkyl is fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring to which the parent structure is attached is cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, and the like. Cycloalkyl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, halo, alkoxy, alkenyl, alkynyl, alkylthio, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocyclyl, cycloalkylthio, heterocycloalkylthio and oxo.
The term "heterocyclyl" refers to a saturated or partially unsaturated mono-or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms wherein one or more of the ring atoms is selected from nitrogen, oxygen, or S (O)m(wherein m is an integer from 0 to 2) but excludes the ring moiety of-O-O-, -O-S-, or-S-S-, the remaining ring atoms being carbon. Preferably 3 to 12 (e.g. 3, 4,5, 6, 7, 8, 9, 10, 11 and 12) ring atoms, of which 1 to 4 (e.g. 1,2, 3 or 4) are heteroatoms; more preferably 3 to 10 ring atoms (e.g., 3, 4,5, 6, 7, 8, 9 or 10), of which 1-3 are heteroatoms; more preferably 6 to 10 ring atoms (e.g., 6, 7, 8, 9 or 10), with 1-3 being heteroatoms; most preferably 5 to 6 ring atoms, of which 1-2 are heteroatoms. Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like. Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups.
The term "spiroheterocyclyl" refers to a 5-to 20-membered polycyclic heterocyclic group in which one atom (referred to as the spiro atom) is shared between monocyclic rings, and in which one or more ring atoms is selected from nitrogen, oxygen, or S (O)m(wherein m is an integer of 0 to 2) and the remaining ring atoms are carbon. It may contain one or more double bonds. Preferably 6 to 14 (e.g. 6, 7, 8, 9, 10, 11, 12, 13 and 14) and more preferably 7 to 10 (e.g. 7, 8, 9 or 10). The spiro heterocyclic group is classified into a mono-spiro heterocyclic group, a di-spiro heterocyclic group or a multi-spiro heterocyclic group, preferably a mono-spiro heterocyclic group and a di-spiro heterocyclic group, according to the number of spiro atoms shared between rings. More preferably 3-membered/5-membered, 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered mono spiroheterocyclyl. Non-limiting examples of spiro heterocyclic groups include:
the term "fused heterocyclyl" refers to 5 to 20 membered polycyclic heterocyclic groups in which each ring in the system shares an adjacent pair of atoms with the other rings in the system, and one or more of the rings may contain oneOr a plurality of double bonds, wherein one or more ring atoms are selected from nitrogen, oxygen or S (O)m(wherein m is an integer of 0 to 2) and the remaining ring atoms are carbon. Preferably 6 to 14, more preferably 7 to 10 (e.g. 7, 8, 9 or 10). They may be classified into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups according to the number of constituent rings, preferably bicyclic or tricyclic, more preferably 5-or 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of fused heterocyclic groups include:
the term "bridged heterocyclyl" refers to 5 to 14 membered (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 membered), polycyclic heterocyclic groups in which any two rings share two atoms not directly attached, which may contain one or more double bonds, wherein one or more of the ring atoms is selected from nitrogen, oxygen or S (O)m(wherein m is an integer of 0 to 2) and the remaining ring atoms are carbon. Preferably 6 to 14, more preferably 7 to 10 (e.g. 7, 8, 9 or 10). They may be classified into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups according to the number of constituent rings, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
such heterocyclyl rings include those wherein the heterocyclyl group described above is fused to an aryl, heteroaryl, or cycloalkyl ring, wherein the ring to which the parent structure is attached is a heterocyclyl, non-limiting examples of which include:
The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio and heterocycloalkylthio.
The term "aryl" refers to a6 to 14 membered (e.g., 6, 7, 8, 9, 10, 11, 12, 13 and 14 membered) all carbon monocyclic or fused polycyclic (i.e., rings which share adjacent pairs of carbon atoms) group having a conjugated pi-electron system, preferably 6 to 10 membered, such as phenyl and naphthyl, most preferably phenyl. Such aryl rings include those wherein the above-described aryl group is fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring, non-limiting examples of which include:
the aryl group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.
The term "heteroaryl" refers to a heteroaromatic system comprising 1 to 4 (e.g., 1,2, 3, and 4) heteroatoms, 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 membered) ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. Heteroaryl is preferably 5 to 10 membered (e.g. 5, 6, 7, 8, 9 or 10), more preferably 5 or 6 membered, e.g. thiadiazole, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl and the like. Such heteroaryl rings include those wherein the heteroaryl group described above is fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring joined together with the parent structure is a heteroaryl ring, non-limiting examples of which include:
heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more, in some cases preferably 1 to 5 (e.g., 1,2, 3, 4 and 5), in some cases more preferably 1 to 3, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.
The above-mentioned cycloalkyl, heterocyclyl, aryl and heteroaryl groups include those derived by removing one hydrogen atom from the parent ring atom, or those derived by removing two hydrogen atoms from the parent ring atom or from two different ring atoms, i.e., "divalent cycloalkyl", "divalent heterocyclyl", "arylene", "heteroarylene".
The term "alkoxy" refers to-O- (alkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy and butoxy. Alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.
The term "bond" refers to a covalent bond of the symbol "-".
The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxyl groups, wherein alkyl is as defined above.
The term "hydroxy" refers to-OH.
The term "haloalkyl" refers to an alkyl group substituted with one or more halogens wherein alkyl is as defined above.
The term "halogen" refers to fluorine, chlorine, bromine or iodine.
The term "amino" refers to the group-NH2。
The term "cyano" refers to — CN.
The term "nitro" means-NO2。
The term "oxo" refers to ═ O.
The term "carboxy" refers to-C (O) OH.
The term "carboxylate" refers to-C (O) O (alkyl), -C (O) O (cycloalkyl), (alkyl) C (O) O-or (cycloalkyl) C (O) O-, wherein alkyl and cycloalkyl are as defined above.
"optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. For example, "a heterocyclic group optionally substituted with an alkyl" means that an alkyl may, but need not, be present, and the description includes the case where the heterocyclic group is substituted with an alkyl and the heterocyclic group is not substituted with an alkyl.
"substituted" means that one or more, preferably 1 to 5, more preferably 1 to 3, hydrogen atoms in the group are independently substituted with a corresponding number of substituents. Those skilled in the art will be able to ascertain (by experiment or theory) without undue effort, substitutions that are possible or impossible. For example, amino or hydroxyl groups having free hydrogen may be unstable in combination with carbon atoms having unsaturated (e.g., olefinic) bonds.
"pharmaceutical composition" means a mixture containing one or more compounds described herein or a physiologically/pharmaceutically acceptable salt or prodrug thereof in admixture with other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate administration to an organism, facilitate absorption of the active ingredient and exert biological activity.
"pharmaceutically acceptable salts" refers to salts of the disclosed compounds which are safe and effective for use in the body of a mammal and which possess the requisite biological activity. Salts may be prepared separately during the final isolation and purification of the compound, or by reacting the appropriate group with an appropriate base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases such as sodium hydroxide and potassium hydroxide, and organic bases such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids as well as organic acids.
The term "solvate" as used herein refers to a physical association of a compound of the present disclosure with one or more, preferably 1-3, solvent molecules, whether organic or inorganic. The physical bonding includes hydrogen bonding. In some cases, for example, when one or more, preferably 1-3, solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be isolated. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.
By "prodrug" is meant a compound that can be converted in vivo under physiological conditions, for example, by hydrolysis in blood, to yield the active parent compound.
The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio, and effective for the intended use.
The term "therapeutically effective amount" as used herein refers to the total amount of each active ingredient sufficient to show a meaningful benefit to the patient, e.g., a sustained reduction in viral load. When an active ingredient is given alone, the term refers to that ingredient alone. When administered in combination, the term refers to the combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, sequentially or simultaneously.
The term "treatment" or similar expressions refer to: (i) inhibiting, i.e., arresting the development of, a disease, disorder, or condition; (ii) ameliorating the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition. In addition, the compounds of the present disclosure may be used to prevent the prophylactic effect of a disease, disorder, or condition in a subject that may be predisposed to the disease, disorder, and/or condition, but has not yet been diagnosed as having the disease.
As used herein, the singular forms "a", "an" and "the" include plural references and vice versa unless the context clearly dictates otherwise.
When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it is meant that the parameter may vary by ± 10%, and sometimes more preferably within ± 5%. As will be understood by those skilled in the art, when a parameter is not a critical parameter, a number is typically given for illustrative purposes only and is not limited to that number.
Inhibitors of protein kinases are widely sought and many small molecules capable of modulating protein kinases have been reported. We have recently found that prodrugs of a class of spiro compounds are potent inhibitors of protein kinases, particularly RAF kinase. These novel spiro compounds possess desirable stability, bioavailability, therapeutic index and toxicity data, which are important to ensure their drugability.
These prodrugs typically comprise a biologically active spiro compound, and the spiro compound is substituted at the nitrogen atom of one or more amide groups with a substituent X1Or X2Substituted, the group X1Or X2Can be metabolized or otherwise converted under conditions to produce an active spiro compound. Without being bound to any relevant practice or theory, it is believed that the phosphate-containing groups enhance the solubility of the biologically active spiro compounds and thus increase oral bioavailability. Phosphoric acid group X1,X2Are found to be metabolized by phosphatases in the digestive tract, thereby forming potentially active parent drugs that are absorbed.
It has been found that biologically active spiro compounds are shown below (see compound 1), when made to contain X (e.g., X)1Or X2) Group (-CH)2-OP(=O)(OH)2) I.e. introduction of X groups (e.g. X) at the superscript asterisk on the amide N1Or X2(see compound A below),
the water solubility and the oral bioavailability are obviously improved. This increased water solubility contributes to better dissolution in the intestinal tract, thereby facilitating oral absorption. Similar improvements in water solubility and oral bioavailability are expected for other active spiro compounds with similarly poor water solubility when formulated as phosphate prodrugs.
Synthesis of the Compounds of the disclosure
For the purpose of the present disclosure, the following technical solutions are adopted in the present disclosure, but the synthesis method of the present disclosure is not limited to the following synthesis methods:
the preparation method of the compound shown in the general formula (III) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof comprises the following steps:
a compound of the formula (IIIA) and Ra-H reaction to give general formula (III);
wherein:
Rwis-SCH3Or an iodine atom;
ring A, R1、R2、R3、L1、RaS, r and q are as defined for the compounds of the general formula (III).
The preparation method of the compound shown in the general formula (IV) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof comprises the following steps:
compounds of the general formula (IVA) and Rb-H reaction to give a compound of general formula (IV);
wherein:
Rwis-SCH3Or an iodine atom;
ring A, R1、R2、R3、L2、RbS, r and q are as defined for the compounds of formula (IV).
The above reaction is preferably carried out in a solvent including, but not limited to: acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1, 4-dioxane, water, N-dimethylformamide and mixtures thereof.
Detailed Description
Examples
The present disclosure is further described below with reference to examples, but these examples do not limit the scope of the present disclosure. If specific conditions for the experimental methods are not specified in the examples of the present disclosure, they are generally according to conventional conditions or recommended by the manufacturers of raw materials and products. No indication is made that the reagents of particular origin are commercially available conventional reagents.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) or/and Mass Spectrometry (MS). NMR shift (. delta.) of 10-6The units in (ppm) are given. NMR was measured using Bruker AVANCE-300, AVANCE-400 or AVANCE-500 NMR spectrometer with deuterated dimethyl sulfoxide (DMSO-d) as the solvent6) Deuterated chloroform (CDCl)3) Deuterated methanol (CD)3OD)。
Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18150X 4.6mm column), Waters 2695-2996 high pressure liquid chromatograph (Gimini C18150X 4.6mm column), or Shimadzu UFLC (Xbridge C185 um 150X 4.6mm column) for High Performance Liquid Chromatography (HPLC) measurements.
Chiral HPLC analytical determination using LC-10A (Shimadzu) or SFC-analytical (Berger Instruments Inc.) or Waters-UPC 2.
MS was measured by using SHIMADZU (ESI) LC-MS (Shimadzu, model: LC-20AD, LCMS-2020), Waters UPLC-QDa (ACQUITY)BEH, 2.1 × 50mm 1.7um chromatography column), Agilent6120(Xbridge C185 um 50 × 4.6mm chromatography column).
Average inhibition rate of kinase and IC50The values were measured using a Microplate reader (BMG, Germany).
The thin layer chromatography silica gel plate adopts HSGF254 of tobacco yellow sea or GF254 of Qingdao, the specification of the silica gel plate used by Thin Layer Chromatography (TLC) is 0.15 mm-0.2 mm, and the specification of the thin layer chromatography separation and purification product is 0.4 mm-0.5 mm.
Silica gel column chromatography generally uses 200-300 mesh silica gel of the Tibet Huanghai silica gel as a carrier.
The CombiFlash rapid preparation machine used Teledyne ISCO or Agela Technologies.
Known starting materials of the present disclosure may be synthesized using or according to methods known in the art, or may be purchased from companies such as ABCR GmbH & co.kg, Acros Organics, Aldrich Chemical Company, nephelo Chemical science and technology (Accela ChemBio Inc), dare chemicals, and the like.
In the examples, the reaction can be carried out in an argon atmosphere or a nitrogen atmosphere, unless otherwise specified.
An argon atmosphere or nitrogen atmosphere means that the reaction flask is connected to a balloon of argon or nitrogen with a volume of about 1L.
The hydrogen atmosphere refers to a reaction flask connected with a hydrogen balloon with a volume of about 1L.
The pressure hydrogenation reaction used a hydrogenation apparatus of the Parr 3916EKX type and a hydrogen generator of the QL-500 type or a hydrogenation apparatus of the HC2-SS type.
The hydrogenation reaction was usually evacuated and charged with hydrogen and repeated 3 times.
The microwave reaction was carried out using a CEM Discover-S908860 type microwave reactor.
In the examples, the solution means an aqueous solution unless otherwise specified.
In the examples, the reaction temperature is, unless otherwise specified, from 20 ℃ to 30 ℃ at room temperature.
The monitoring of the progress of the reaction in the examples employed Thin Layer Chromatography (TLC), a developing solvent used for the reaction, a system of eluents for column chromatography used for purifying compounds and a developing solvent system for thin layer chromatography including: a: dichloromethane/methanol system, B: the volume ratio of the solvent is adjusted according to the polarity of the compound. The elution system for column chromatography, thin layer chromatography and CombiFlash flash rapid prep of purified compounds comprises: a: dichloromethane and methanol, B: hexane and ethyl acetate. The volume ratio of the solvent may be adjusted depending on the polarity of the compound, and a small amount of a basic agent such as ammonia or an acidic agent such as acetic acid may be added in some cases.
The final compound was purified by Shimadzu (LC-20AD, SPD20A) preparative HPLC (Phenomenex Gemini-NX 5uM C1821.2X 100mm column), Waters 2767(Sunfire Pre C1810 uM 19X 250mm column), or Waters 2767-QDa (Xbridge Pre C1810 uM 19X 250mm column) in water/MeOH or water/CH3Purification in CN elution System and optional additives such as HCOOH, TFA and NH4HCO3。
The following abbreviations are used in the examples:
DIPEA is N, N-diisopropylethylamine,
HATU is 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethyluronium hexafluorophosphate,
the DCM is the methylene chloride, and the DCM is the methylene chloride,
DMF is N, N-dimethylformamide,
the DMSO is dimethyl sulfoxide, and the DMSO is dimethyl sulfoxide,
the EtOAc is ethyl acetate which is the mixture of the ethyl acetate,
prep HPLC for preparative high performance liquid chromatography,
NMR is the nuclear magnetic resonance of a proton,
MS is mass spectrometry, where (+) refers to positive mode, typically giving M +1 (or M + H) absorption, where M ═ molecular weight.
General reaction scheme
1
General reaction scheme
2
General reaction scheme
3
General reaction scheme
4
Example 1
N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -5- (trifluoromethyl) pyridazine-3-carboxamide 1
First step of
7-bromo-2 ',3',5',6' -tetrahydrospiro [ chromane-2, 4' -pyran ] -4-one 1c
Pyrrolidine (1.81g, 2.12mL, 25.4mmol) was added to a solution of 1- (4-bromo-2-hydroxyphenyl) ethan-1-one 1a (10.9g, 50.7mmol) and tetrahydro-4H-pyran-4-one 1b (6.60g, 65.9mmol) in methanol (100mL) at room temperature. The reaction was stirred at room temperature overnight. The reaction mixture was concentrated, and to the resulting residue were added water (20mL), a hydrochloric acid solution (1N, 40mL) and ethyl acetate (200 mL). The organic phase was washed with water (25 mL. times.2), dried, filtered, and concentrated under reduced pressure to give the title compound 1c (11.8g, yield: 78.1%) which was used without purification.
1HNMR(400MHz,CDCl3)δ1.77-1.83(m,2H),1.97-2.01(m,2H),2.76(s,2H),3.82-3.88(m,4H),7.17(d,1H),7.27(s,1H),7.74(d,1H)。
Second step of
(Z) -7-bromo-2 ',3',5',6' -tetrahydrospiro [ chromane-2, 4' -pyran ] -4-one oxime 1d
To a solution of compound 1c (9g, 30.29mmol) in ethanol (90mL) were added hydroxylamine hydrochloride (6.31g, 90.87mmol) and sodium acetate (7.45g, 90.87mmol), and the reaction was heated to reflux and stirred for 2 hours. The reaction solution was diluted with saturated sodium chloride solution (150mL), extracted with ethyl acetate (100 mL. times.2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound 1d as a crude product (9g, yield: 95%).
MS m/z(ESI):312.1[M+H]+
The third step
(Z) -7-bromo-2 ',3',5',6' -tetrahydrospiro [ chromane-2, 4' -pyran ] -4-one O-p-toluenesulfonyl oxime 1e
To a solution of compound 1d (2g, 8.64mmol) in dichloromethane (100mL) was added triethylamine (4.72g, 46.61mmol) and p-toluenesulfonic anhydride (12.17g, 37.29 mmol). The reaction was stirred at room temperature for 2 hours. Then, water (150mL) and methylene chloride (150mL) were added for extraction, and the organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate: n-hexane ═ 0:1 to 1:10, 200 to 300 mesh silica gel) to obtain the title compound 1e (9g, yield: 62%).
1H NMR(400MHz,DMSO):δ7.91(d,2H),7.57(d,1H),7.50(d,2H),7.29(d,1H),7.18(dd,1H),3.61(d,4H),3.02(s,2H),2.41(s,3H),1.72-1.57(m,4H)。
MS m/z(ESI):465.9[M+H]+
The fourth step
8-bromo-2 ',3',5',6' -tetrahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -4(5H) -one 1f
To a solution of compound 1e (8.8g, 18.87mmol) in dichloromethane (100mL) at 0 deg.C was added aluminum trichloride (10.06g, 75.48mmol), and the mixture was stirred at 0-10 deg.C for 2 hours. Saturated sodium bicarbonate solution was added for dilution (100mL) and concentrated HCl was added to adjust the pH to 1. The mixture was extracted with dichloromethane (150mL × 2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residuePurification by silica gel column chromatography (ethyl acetate: hexane ═ 0:1 to 9:1, 200 to 300 mesh silica gel) gave the title compound 1f (3g, yield: 51%).1HNMR(400MHz,CDCl3),δ7.61(s,1H),7.30(s,1H),7.23(s,1H),6.90(d,1H),3.98-3.85(m,4H),2.57(s,2H),2.03-2.00(m,2H),1.88-1.81(m,2H)。
MS m/z(ESI):312.0[M+H]+
The fifth step
8- (5-amino-2-methylphenyl) -2',3',5',6' -tetrahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -4(5H) -one 1g
To a solution of compound 1f (1.5g, 4.81mmol) in 1, 4-dioxane (20mL) were added water (10mL), sodium carbonate (1.02g, 9.61mmol), 1-bis (diphenylphosphino) ferrocene palladium dichloride (350.00mg, 478.14umol) and 4-methyl-3- (4,4,5, 5-tetramethyl- [1,3,2] dioxaborolan-2-yl) -aniline (1.34g, 5.77mmol), and the reaction was stirred under nitrogen at 90 ℃ for 4 hours. The reaction was cooled and extracted with ethyl acetate (30mL), the organic phase was collected, washed with water (10mL × 3) and saturated sodium chloride solution (10mL), dried over anhydrous sodium sulfate, filtered and concentrated, and the resulting crude product was purified by silica gel column chromatography (dichloromethane: methanol ═ 30:1) to obtain 1g of the title compound (1.6g, yield 98%).
1H NMR(400MHz,CDCl3):δ7.64(s,1H),7.08-7.01(m,4H),6.64(dd,1H),6.58(d,1H),3.95-3.92(m,2H),3.85-3.77(m,2H),3.62(brs,2H),2.59(s,2H),2.15(s,3H),2.04-2.00(m,2H),1.87-1.79(m,2H)。
MS m/z(ESI):339.1[M+H]+
The sixth step
N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -5- (trifluoromethyl) pyridazine-3-carboxamide 1
Compound 1g (140mg, 413.71umol), 5- (trifluoromethyl) pyridazine-3-carboxylic acid (70mg, 64.48umol), 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (235.96mg, 620.57umol) and triethylamine (125.59mg, 1.24mmol) were added to N, N-dimethylformamide (5mL), respectively, and the mixture was stirred at room temperature for 12 hours. The completion of the reaction was monitored by LC-MS. Extraction with ethyl acetate (20mL) collected the organic phase, washed with saturated sodium chloride solution, dried and concentrated to give the crude product which was prepared by thin layer chromatography to give the title compound 1(93mg, 44% yield).
1H NMR(400MHz,DMSO-d6):δ11.26(s,1H),9.96(d,1H),9.82(s,1H),8.57(d,1H),7.88(d,1H),7.86(s,1H),7.31(d,1H),7.17-7.09(m,2H),7.05(d,1H),3.81-3.78(m,2H),3.72-3.68(m,2H),2.50(s,2H),2.25(s,3H),1.87-1.74(m,4H)。
19F NMR(376.5MHz,DMSO-d6):δ-63.08。
MS m/z(ESI):513.2[M+H]+
Examples 2 to 7 were prepared using the foregoing method and general procedure described in example 1, but substituting the appropriate aryl carboxylic acid in step 6 as described in the foregoing schemes and examples. The required starting materials are either commercially available, described in the literature, or readily synthesized by those skilled in the art from commercial reagents using routine reactions without undue experimentation.
Example 2
N-4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -2- (trifluoromethyl) isonicotinamide 2
1HNMR(400MHz,CD3OD),δ8.92(d,1H),8.32(s,1H),8.14(d,1H),7.66(s,1H),7.64(d,1H),7.33(d,1H),7.15(s,2H),7.10(s,1H),3.98(t,2H),3.84-3.82(m,2H),2.60(s,2H),2.30(s,3H),2.03-2.00(m,2H),1.89-1.84(m,2H).
MS m/z(ESI):512.0[M+1]+
Example 3
N-4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -2- (trifluoromethyl) pyrimidine-5-carboxamide 3
1H NMR(400MHz,DMSO-d6)δ10.75(s,1H),9.83(s,1H),9.50(s,2H),7.78–7.59(m,2H),7.40–7.28(m,1H),7.17–7.07(m,2H),7.04(d,1H),3.87–3.63(m,4H),2.62(s,2H),2.25(s,3H),1.92–1.69(dt,4H).
LCMS:MS m/z(ESI):513.0[M+H]+.
Example 4
2- (difluoromethoxy) -N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin 2,4' -pyran ] -8-yl) phenyl) isonicotinamide 4
1H NMR(400MHz,DMSO-d6):δ10.51(s,1H),9.82(s,1H),8.46(d,1H),7.78-7.56(m,5H),7.30(d,1H),7.11-7.08(m,2H),7.03(s,1H),3.83-3.60(m,4H),2.50(s,2H),2.23(s,3H),1.86-1.76(m,4H).
19F NMR(376.5MHz,DMSO-d6):δ-87.37(s,2F).
MS m/z(ESI):510.2[M+H]+
Example 5
N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) 2- (trifluoromethoxy) isonicotinamide 5
1H NMR(400MHz,DMSO-d6):δ10.56(s,1H),9.82(s,1H),8.58(d,1H),7.90(d,1H),7.75(s,1H),7.70(d,1H),7.65(s,1H),7.30(d,1H),7.14-7.09(m,2H),7.03(s,1H),3.83-3.68(m,4H),2.50(s,2H),2.23(s,3H),1.86-1.72(m,4H).
19F NMR(376.5MHz,DMSO-d6):δ-55.14(s).
MS m/z(ESI):528.2[M+H]+
Example 6
N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -6- (trifluoromethyl) pyridazine-3-carboxamide 6
1H NMR(400MHz,DMSO):δ11.22(s,1H),9.82(s,1H),8.58-8.50(m,2H),7.87-7.84(m,2H),7.32(d,1H),7.17-7.09(m,2H),7.05(d,1H),3.84-3.77(m,2H),3.72-3.67(m,2H),2.50(s,2H),2.25(s,3H),1.87-1.73(m,4H).
19F NMR(376.5MHz,DMSO-d6):δ-65.67
LCMS:MS m/z(ESI):513.1[M+H]+
Example 7
N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -6- (trifluoromethoxy) nicotinamide 7
1H NMR(400MHz,DMSO-d6)δ10.47(s,1H),9.82(s,1H),8.90(d,1H),8.50(dd,1H),7.76–7.59(m,2H),7.52–7.39(m,1H),7.30(d,1H),7.22–7.09(m,2H),7.03(d,1H),3.91–3.76(m,2H),3.73-3.65(dt,2H),2.62(s,2H),2.24(s,3H),1.90–1.73(m,4H).
LCMS:MS m/z(ESI):528.0[M+H]+.
Example A1
(8- (2-methyl-5- (5- (trifluoromethyl) pyridazin-3-carboxamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepine-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A1
First step of
N- (4-methyl-3- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl) -5- (trifluoromethyl) pyridazine-3-carboxamide A1c
To a solution of 4-methyl-3- (4,4,5, 5-tetramethyl- [1,3,2] dioxaborolan-2-yl) -phenylamine A1a (613mg, 2.63mmol) in N, N-dimethylformamide (12mL) were added 5- (trifluoromethyl) pyridazine-3-carboxylic acid A1b (500mg, 2.63mmol) and 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (1.02g, 2.68mmol), followed by addition of N, N-diisopropylethylamine (1.5mL, 9.07mmol) at 0 ℃. The resulting mixture was stirred at room temperature for 1 hour. Ethyl acetate (150mL) was added and the organic phase was washed successively with saturated ammonium chloride solution (40mL), saturated sodium bicarbonate solution (40mL) and saturated sodium chloride solution (40 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (hexane/ethyl acetate as eluent) to give the title compound A1c (873mg, yield: 82%).
MS m/z(ESI):408.3[M+H]+
Second step of
8-bromo-5- ((methylthio) methyl) -2',3',5',6' -tetrahydro-3H-spiro [ benzo [ b ] [1,4] -oxazepin-2, 4' -pyran-4 (5H) -one A1d
To a reaction flask were added compound 1f (31mg, 0.10mmol) and N, N-dimethylformamide (0.5 mL). The mixture was cooled to 0 ℃ and sodium hydride (5mg, 0.125mmol) was added and stirred for 30 min. Chloromethyl methyl sulfide (12mg, 0.125mmol) and tetrabutylammonium iodide (48mg, 0.15mmol) were added thereto. The mixture was stirred at room temperature for 1 hour and reacted at 45 ℃ for 18 hours. The reaction was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (2X 5 mL). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by flash column chromatography (ethyl acetate: hexane ═ 0 to 30:100) to give the title compound A1d (25mg, yield 67.2%).
MS m/z(ESI):373.0[M+1]+
The third step
N- (4-methyl-3- (5- ((methylthio) methyl) -4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -5- (trifluoromethyl) pyridazine-3-carboxamide A1e
A reaction flask was charged with A1d (330mg, 0.81mmol), compound A1c (361mg, 0.97mmol), [1,1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (59mg, 0.081mmol) and cesium carbonate (528mg, 1.62mmol), and reacted under an argon atmosphere. To the reaction mixture was added a solution of 1, 4-dioxane (10 mL)/water (2mL) and stirred at 105 ℃ for 3 hours. After cooling, water was added to the reaction mixture, which was extracted with ethyl acetate (3X 25 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, filtered and the filtrate was concentrated under reduced pressure. The obtained residue was purified by flash column chromatography (ethyl acetate: dichloromethane: 0:100 to 65:100) to obtain the title compound A1e (250mg, yield: 54%).
MS m/z(ESI):573.2[M+1]+
The fourth step (8- (2-methyl-5- (5- (trifluoromethyl) pyridazin-3-carboxamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A1
A mixture of Compound A1e (200mg, 0.35mmol), phosphoric acid (1.37g, 14.0mmol) and 3A molecular sieves (200mg) in tetrahydrofuran (6mL) was stirred at room temperature for 15 minutes and cooled to 0 ℃. N-iodosuccinimide (158mg, 0.7mmol) was added and reacted at 0 ℃ for 30 minutes and at room temperature for 1 hour, respectively. The reaction mixture was filtered to remove solids. The filtrate was diluted with methanol and cooled to 0 ℃. The resulting mixture was quenched with saturated sodium thiosulfate solution, adjusted to pH7 with 2N sodium hydroxide, filtered through celite, washed with methanol, and concentrated under reduced pressure. The resulting residue was purified by high performance liquid chromatography (0-50% acetonitrile in water + 0.2% ammonium hydrogencarbonate) to give the title compound A1(141mg, yield: 65%).
1H NMR(400MHz,CH3OH-d4)δ9.63(d,1H),8.54(d,1H),7.73(d,1H),7.67(d,2H),7.24(d,1H),7.18(dd,1H) 6.97(d,1H),5.45(s,2H),3.86(td,2H),3.70(dt,2H),2.51(s,2H),2.20(s,3H),1.87(d,2H),1.73(ddd, 2H). In CH3OH-d4No two-OH groups and NH on the phosphoric acid were observed.
31P NMR(400MHz,CH3OH-d4)δ-1.53(s)。
MS m/z(ESI):623.0[M+1]+
Examples a 2-a 7 were prepared using the above-described method and general procedure described in example a1, but replacing the appropriate arylboronic acid ester in step 3 as described in the foregoing schemes and examples. The required starting materials are either commercially available, described in the literature, or readily synthesized by those skilled in the art from commercial reagents using routine reactions without undue experimentation.
Example A2
(8- (2-methyl-5- (2- (trifluoromethyl) isonicotinamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepine-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A2
Example a2 was prepared using the foregoing method and the general method described in example a1, but substituting the appropriate arylboronic acid ester in step 3 as described in the foregoing schemes and examples. The necessary starting materials are either commercially available or obtained as described in the literature or synthesized by one skilled in the art of organic synthesis from commercially available reagents using conventional reactions.
1H NMR(400MHz,CH3OH-d4) δ 8.81(d,1H),8.21(s,1H),8.03(dd,1H),7.72(d,1H),7.59(dd,1H),7.50(d,1H),7.22(d,1H),7.16(dd,1H),6.96(d,1H),5.45(d,2H), 3.93-3.77 (m,2H),3.70(dt,2H),2.51(s,2H),2.19(s,3H),1.87(d,2H),1.73(ddd, 2H). In CH3No two-OH groups and NH on phosphoric acid were observed in OH-d 4.
31P NMR(400MHz,CH3OH-d4)δ-1.40(s)
MS m/z(ESI):622.0[M+H]+
Example A3
(8- (2-methyl-5- (2- (trifluoromethyl) pyrimidine-5-carboxamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepine-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A3
1H NMR(400MHz,CH3OH-d4) Δ 9.43(s,2H),8.06(d,1H),7.71(dd,1H),7.55(d,1H),7.31(d,1H),7.24(dd,1H),7.00(d,1H),5.50(brs,2H),3.98-3.92(m,2H),3.82-3.76(m,2H),2.58(s,2H),2.28(s,3H),1.98-1.93(m,2H),1.85-1.78(m,2H) in CH3No two-OH groups and NH on phosphoric acid were observed in OH-d 4.
19F NMR(376.5MHz,CH3OH-d4):δ-71.98.
LCMS:MS m/z(ESI):621.0[M-H]-
Example A4
(8- (5- (2- (difluoromethoxy) isonicotinamido) -2-methylphenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepin-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A4
1H NMR(400MHz,CH3OH-d4) Δ 8.37(d,1H),8.00(d,1H),7.69-7.64(m,2H),7.60(t,1H),7.54(d,1H),7.44(s,1H),7.29(d,1H),7.24(d,1H),7.01(d,1H),5.50(brs,2H),3.98-3.91(m,2H),3.81-3.76(m,2H),2.58(s,2H),2.27(s,3H),1.98-1.94(m,2H),1.85-1.77(m,2H) in CH3No two-OH groups and NH on phosphoric acid were observed in OH-d 4.
19F NMR(376.5MHz,CH3OH-d4):δ-90.49.
LCMS:MS m/z(ESI):618.0[M-H]-
Example A5
(8- (2-methyl-5- (2- (trifluoromethoxy) isonicotinamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepine-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A5
1H NMR(400MHz,CH3OH-d4) Δ:8.48(d,1H),7.0(d,2H),7.67(dd,1H),7.61(s,1H),7.56(d,1H),7.31(d,1H),7.25(dd,1H),7.05(d,1H),5.55(brs,2H),3.98-3.92(m,2H),3.81-3.77(m,2H),2.59(s,2H),2.27(s,3H),1.98-1.93(m,2H),1.86-1.77(m,2H) in CH3No two-OH groups and NH on phosphoric acid were observed in OH-d44.
31P NMR(162.0MHz,CH3OH-d4):δ:-1.62
19F NMR(376.5MHz,CH3OH-d4):δ:-58.03
LCMS:MS m/z(ESI):636.0[M-H]-.
Example A6
(8- (2-methyl-5- (6- (trifluoromethyl) pyridazin-3-carboxamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] [1,4] oxazepine-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A6
1H NMR(400MHz,CH3OH-d4) Δ 8.60(d,1H),8.34(d,1H),8.06(d,1H),7.78-7.73(m,2H),7.33(d,1H),7.27(dd,1H),7.03(d,1H),5.50(brs,2H),3.99-3.92(m,2H),3.81-3.77(m,2H),2.59(s,2H),2.29(s,3H),1.99-1.95(m,2H),1.86-1.77(m,2H) in CH3No two-OH groups and NH on phosphoric acid were observed in OH-d 4.
19F NMR(376.5MHz,CH3OH-d4):δ-68.55.
LCMS:MS m/z(ESI):621.0[M-H]-
Example A7
(8- (2-methyl-5- (6- (trifluoromethoxy) nicotinamido) phenyl) -4-oxo-2 ',3,3',4,5',6' -hexahydro-5H-spiro [ benzo [ b ] ] [1,4] oxazepine-2, 4' -pyran ] -5-yl) dihydrogenphosphate methyl ester A7
1H NMR(400MHz,CH3OH-d4) Δ 8.86(d,1H),8.45(dd,1H),7.89(d,1H),7.67(dd,1H),7.53(d,1H),7.31-7.23(m,3H),7.03(d,1H),5.53(brs,2H),3.98-3.92(m,2H),3.81-3.76(m,2H),2.59(s,2H),2.27(s,3H),1.98-1.93(m,2H),1.85-1.77(m,2H) in CH3No two-OH groups and NH on phosphoric acid were observed in OH-d 4.
19F NMR(376.5MHz,CH3OH-d4):δ:-58.05
31P NMR(162.0MHz,CH3OH-d4):δ:0.04
LCMS:MS m/z(ESI):636.0[M-1]-.
Example B1
(N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ B ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -5- (trifluoromethyl) pyridazine-3-carboxamido) dihydrogenphosphate methyl ester B1
First step of
N- (4-methyl-3- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl) -N- ((methylthio) methyl) -5- (trifluoromethyl) pyridazine-3-carboxamide B1a
Compound A1c (500mg, 1.23mmol) and N, N-dimethylformamide (10mL) were added to the reaction flask. The reaction mixture was cooled to 0 deg.C, sodium hydride (74mg, 1.85mmol) was added, and stirred for 30 minutes. Chloromethyl methyl sulfide (236mg, 2.46mmol) and tetrabutylammonium iodide (1.19g, 3.69mmol) were added thereto. The mixture was stirred at room temperature for 1 hour and reacted at 45 ℃ for 18 hours. After cooling, the reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (2 × 50 mL). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by flash chromatography (ethyl acetate: hexane: 0-30:100) to give the title compound B1a (112mg, yield: 20%).
MS m/z(ESI):468.0[M+1]+
Second step of
N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ B ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -N- ((methylthio) methyl) -5- (trifluoromethyl) pyridazine-3-carboxamide B1B
Compound 1f (231mg, 0.74mmol), B1a (265mg, 0.57mmol), [1,1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (44mg, 0.06mmol) and cesium carbonate (372mg, 1.14mmol) were added to a reaction flask and reacted under argon. 1, 4-dioxane (66 mL)/water (1.2mL) was added to the reaction mixture and stirred at 105 ℃ for 3 hours. After cooling, water was added to the reaction mixture, which was extracted with ethyl acetate (3X 25 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, filtered and the filtrate was concentrated under reduced pressure. The obtained residue was purified by flash column chromatography (ethyl acetate: dichloromethane: 0:100 to 75:100) to obtain the title compound B1B (190mg, yield: 58%).
MS m/z(ESI):573.0[M+1]+
The third step
(N- (4-methyl-3- (4-oxo-2 ',3',4,5,5',6' -hexahydro-3H-spiro [ benzo [ B ] [1,4] oxazepin-2, 4' -pyran ] -8-yl) phenyl) -5- (trifluoromethyl) pyridazine-3-carboxamido) dihydrogenphosphate methyl ester B1
A mixture of compound B1B (155mg, 0.27mmol), phosphoric acid (1.06g, 10.8mmol) and 3A molecular sieves (80mg) in tetrahydrofuran (5mL) was stirred at room temperature for 15 minutes and then cooled to 0 ℃. N-iodosuccinimide (122mg, 0.54mmol) was added and reacted at 0 ℃ for 30 minutes and at room temperature for 1 hour, respectively. The reaction mixture was filtered to remove solids. The filtrate was diluted with methanol and then cooled to 0 ℃. The resulting mixture was quenched with saturated sodium thiosulfate solution, adjusted to pH7 with 2N NaOH, filtered through celite, washed with methanol, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by high performance liquid chromatography (0-50% acetonitrile in water + 0.2% ammonium hydrogencarbonate) to give the title compound B1(130mg, yield: 77%).
1H NMR(400MHz,CH3OH-d4) δ 9.33(s,1H),8.13(s,1H), 7.16-6.94 (m,4H),6.84(d,1H),6.76(s,1H),5.61(s,2H),3.86(td,2H),3.71(dt,2H),2.45(s,2H),2.05(s,3H),1.87(d,2H),1.73(ddd, 2H). In CH3No two-OH groups on the phosphoric acid were observed in OH-d 4.
31P NMR(400MHz,CH3OH-d4)δ-1.28(s)。
MS m/z(ESI):623.0[M+1]+
Test example 1 pharmacokinetic testing of Compounds of the disclosure
The instrument comprises the following steps:
API4000 triple quadrupole tandem mass spectrometer, applied biosystems, usa;
shimadzu LC-30AD ultra performance liquid chromatography system, Shimadzu, japan.
Chromatographic conditions are as follows:
a chromatographic column: welch Xtimate C181.8 μm 30x2.1mm
Mobile phase A: aqueous solution containing 0.5% formic acid, 5mM ammonium acetate (gradient elution)
Mobile phase B: 0.5% formic acid, 5mM ammonium acetate in 95% acetonitrile/water (gradient elution)
Column temperature: 35 deg.C
Preparation of test samples
Mu.l of plasma sample was mixed with 50. mu.L of internal standard solution (100ng/mL) and 200. mu.L of CH3CN precipitant was mixed and the solution was vortexed and stirred for 5 minutes, then centrifuged for 10 minutes (4000 rpm). 8 μ L of supernatant was sampled for LC/MS/MS analysis.
The process is as follows:
in the PK study in SD rats, animals of each group (N ═ 4, male 2, female 2) were fasted overnight. The intragastric administration (ig) group was administered by intragastric gavage. Blood samples (0.2ml) were collected from the orbit at time points 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 11.0, and 24.0 hours, placed in an ethidene-diaminediacetic acid tetrapotassium (K2 EDTA) anticoagulated blood collection tube, and then centrifuged at 4 deg.C (10,000rpm) for 1 minute to obtain plasma. Plasma samples were separated over 1 hour and stored at-20 ℃ until analyzed by liquid chromatography-tandem mass spectrometry (LC/MS). The whole process from blood collection to centrifugation was performed under ice bath conditions. Rats were fed 2 hours after dosing.
Data analysis
Pharmacokinetic parameters were derived by non-compartmental analysis of plasma concentrations (determined by LC/MS) versus time point data. Peak concentrations (Cmax) and Cmax times were recorded directly from experimental observations. Calculating the area under the curve from time zero to the last sample time (AUC) using a combination of linear and logarithmic trapezoidal summations0-t)。
As a result:
in rat gavage (ig) dosing experiments, the prodrug compound a1 in formulation a was dosed at 20mpk and 100mpk (× for a1, dose 1 equivalent of the parent drug). Plasma exposure levels indicated that only prodrug compound 1 was detected and prodrug compound a1 was not found. AUC at 20mpk0-t 19922ng/ml × h; AUC at 100mpk0-t 132780ng/ml × h (table 1).
In sharp contrast, also in the rat gavage (ig) dosing experiment, the original drug compound 1 was tried in different formulations using different doses, the best AUC of which0T can only reach around 22000ng/ml h (Table 1). Prodrug compound a1 of the present disclosure showed significant AUC compared to the original drug compound 10-t is improved.
A similar trend was also observed in compound B1: in rat gavage experiments (ig), prodrug compound B1 was also administered at doses of 20mpk and 100mpk (× for B1, dose 1 equivalent of the parent drug). Plasma exposure levels indicated that only prodrug compound 1 was detected and prodrug compound B1 was not found. AUC at 20mpk0-t 20736ng/ml h; AUC at 100mpk0-t 102170ng/ml × h (table 1). Compared to the original drug compound 1, the present disclosureProdrug compound B1 also showed significant AUC0-t is improved.
Table 1 pharmacokinetic data for the compounds of the disclosure.
Note that for prodrug compounds a1 and B1, the dose is 1 equivalent of the parent drug compound.
Formulation a 5% dimethyl sulfoxide + 20% PEG400+ 70% (10% TPGS) + 5% (1% HPMC K100LV)
Formulation b, 5% dimethyl sulfoxide, 40% PEG400, 5% ethanol and 50% propylene glycol
Formulation c, 5% dimethyl sulfoxide + 25% PEG400+ 35% RH40+ 35% water
Abbreviations:
Cmaxmaximum plasma concentration
PEG400 polyethylene glycol 400
HPMC K100LV hydroxypropyl methylcellulose (HPMC) K100LV
TPGS D-alpha-tocopheryl polyethylene glycol 1000 succinate
Test example 2:
biological evaluation
cRAF kinase Activity inhibition assay
The ability of a compound to inhibit cRAF kinase activity was tested in vitro using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay, and assayed according to kit instructions. Briefly, human recombinant cRAF protein kinase (BPS Bioscience, catalog No. 40008) was first diluted to 0.027 ng/. mu.l using 1-fold kinase buffer a (Life Tech, catalog No. PV6135, 5-fold original concentration, diluted 1-fold with water); fluorescein-labeled MAP2K1(Life Tech, catalog number PV4812) was diluted to 0.5 μ M; ATP (Life Tech, Cat # PV3227) was diluted to 20. mu.M; 2.5ul of each of the diluted reagents described above was then added to a 384 well plate (Perkinelmer, ProxiPlate-384 Plus, Cat. No. 60)08280) Mixing, and mixing; add 2.5 μ L of the compound after gradient dilution to the above mixture (blank for the same volume of dilution without compound); then, 10. mu.l of 400-fold diluted LanthaScreen Tb-pMAP2K1(pSer217/221) antibody (Life Tech, Cat. No. PV4817) was added and incubated at room temperature for 1 hour. Data were read on PHERAStar FSX, percent inhibition of kinase activity by compound was calculated (blank 0% inhibition, no kinase control 100% inhibition), dose response curves were generated using GraphPad Prism software, and median Inhibitory Concentration (IC) was calculated by non-linear regression analysis50)。
BRAFWTInhibition of kinase Activity
Detection of compound vs BRAF in vitro using time-resolved fluorescence resonance energy transfer (TR-FRET) assayWTThe inhibitory capacity of kinase activity was determined according to the kit instructions. Briefly, human recombinant BRAF was first diluted 1-fold with 1-fold kinase buffer a (Life Tech, catalog No. PV6135, 5-fold original concentration, 1-fold diluted with water)WTProtein kinase (BPS Bioscience, catalog number 40065) diluted to 0.027 ng/. mu.L; fluorescein-labeled MAP2K1(Life Tech, catalog number PV4812) was diluted to 0.5 μ M; ATP (Life Tech, Cat # PV3227) was diluted to 20. mu.M; 2.5ul of each of the diluted reagents described above was added to a 384 well plate (Perkinelmer, ProxiPlate-384 Plus, cat. No. 6008280) and mixed well; add 2.5 μ L of the compound after gradient dilution to the above mixture (blank for the same volume of dilution without compound); then, 10. mu.l of 400-fold diluted LanthaScreen Tb-pMAP2K1(pSer217/221) antibody (Life Tech, Cat. No. PV4817) was added and incubated at room temperature for 1 hour. Data were read on PHERAStar FSX, percent inhibition of kinase activity by compound was calculated (blank 0% inhibition, no kinase control 100% inhibition), dose response curves were generated using GraphPad Prism software, and median Inhibitory Concentration (IC) was calculated by non-linear regression analysis50)。
BRAFV600EInhibition of kinase Activity
Detection of compound vs BRAF in vitro using time-resolved fluorescence resonance energy transfer (TR-FRET) assayV600EInhibitory Activity of kinaseThe assay was performed according to the kit instructions. Briefly, human recombinant BRAFV600E protein kinase (BPS Bioscience, catalog No. 40533) was first diluted to 0.027 ng/. mu.l using 1-fold kinase buffer a (Life Tech, catalog No. PV6135, 5-fold original concentration, diluted 1-fold with water); fluorescein-labeled MAP2K1(Life Tech, catalog number PV4812) was diluted to 0.5 μ M; ATP (Life Tech, Cat # PV3227) was diluted to 20. mu.M; 2.5ul of each of the diluted reagents described above was added to a 384 well plate (Perkinelmer, ProxiPlate-384 Plus, cat. No. 6008280) and mixed well; add 2.5 μ L of the compound after gradient dilution to the above mixture (blank for the same volume of dilution without compound); then, 10. mu.L of 400-fold diluted LanthaScreen Tb-pMAP2K1(pSer217/221) antibody (Life Tech, Cat. No. PV4817) was added and incubated at room temperature for 1 hour. Data were read on PHERAStar FSX, percent inhibition of kinase activity by compound was calculated (blank 0% inhibition, no kinase control 100% inhibition), dose response curves were generated using GraphPad Prism software, and median Inhibitory Concentration (IC) was calculated by non-linear regression analysis50)。
And (4) conclusion: the disclosed compounds are potential inhibitors of RAF.
Test example 3 solubility testing of compounds of the present disclosure in PBS7.4 and Fassif
3.1 preparation of reference solution:
a 10 μ L stock solution of a sample to be tested (concentration 10mM, dissolved in DMSO) and 990 μ L of an organic mixed solvent (usually DMSO: acetonitrile: ethanol ═ 1:1:1) were precisely measured in a 2mL sample bottle and mixed well to obtain a clear 100 μ M sample solution as a reference solution.
3.2 preparation of compound PBS7.4 solution:
weighing a proper amount of a test compound, and adding DMSO or DMSO: acetonitrile: ethanol 1:1:1 was dissolved to prepare a 10mM stock solution of the test compound. Precisely measuring 10 mu L of stock solution of the compound to be detected and 990 mu L of PBS solution with pH7.4 in a 2mL sample bottle, and uniformly mixing, wherein the final DMSO concentration of the solution is 1% (v/v). The solution was prepared in two portions in parallel, shaken on a flat bed at room temperature for 24 hours, centrifuged at 5000rpm for 20min, and the supernatant was transferred to a liquid chromatograph for analysis.
3.3 preparation of compound Fassif solution:
dissolving 1mg of sample to be detected into 900 mu L of Fassif solution, strongly mixing, and preparing two solutions in parallel; after shaking in a 37 ℃ water bath for 24 hours, the mixture was centrifuged at 4000rpm for 30min, and the supernatant was transferred to liquid chromatography as a sample solution.
3.4. Data processing
Solubility (μ M) — peak area of sample/peak area of reference — (μ M) — (dilution of sample solution). The final solubility was taken as the average of the two measurements.
TABLE 3 solubility testing of Compounds of the present disclosure
And (4) conclusion: prodrug molecule example a1 is able to significantly improve solubility over the parent compound example 1. The other prodrug molecules A3, a4, a5 and a6 all have good solubility.
The foregoing embodiments and examples are provided for illustration only and are not intended to limit the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art based upon this disclosure, and such changes and modifications may be made without departing from the spirit and scope of the invention. All documents cited are incorporated herein by reference in their entirety without admission that they are prior art.
Claims (20)
1. A compound of the general formula (I),
or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,
wherein:
G1selected from O, S, C (═ O), C (═ O) NH and NR6、CR7R8And S (═ O)2;
Ring a is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
X1and X2Are the same or different and are each independently a hydrogen atom or L-R0(ii) a Provided that X is1And X2Not being hydrogen atoms at the same time;
l is selected from-CH2-、-C(=O)O(CQ1Q2)n-and-C (═ O) S (CQ)1Q2)n-;
R0Selected from-OP (═ O) (OH)2、-OP(=O)(OH)-OP(=O)(OH)2、-OC(=O)Q3、-OC(=O)OQ3、-OC(=O)NHQ3、-OP(=O)(OQ4)2、-O-C(=O)(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)(CQ1Q2)n-Cy-OP(=O)(OH)2、-OC(=O)CH=CHC(=O)OH、-O-C(=O)-O-(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)-NH-(CQ1Q2)n-OP(=O)(OH)2、-OC(=O)CH(Q5)-NQ6Q7and-NQ6Q7;
Cy is aryl or heteroaryl, each independently optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
Q1、Q2、Q3and Q5Are identical or different and are each independently selected from the group consisting of a hydrogen atom, an alkyl group and-C (═ O) R9Wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitroAlkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
Q4selected from alkyl, -CH2OC(=O)R9and-CH2-OC(=O)OR9;
Q6And Q7Are identical or different and are each independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, -C (═ O) R9Cycloalkyl, heterocyclyl, aryl and heteroaryl;
R1the same or different, and each is independently selected from the group consisting of hydrogen atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl, each of which is independently optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R2aand R2The same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R3the same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R4and R5The same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R6selected from the group consisting of hydrogen atom, alkyl group, haloalkyl group, hydroxyl group, hydroxyalkyl group, amino group, cycloalkyl group, heterocyclic group, C (O) OR10、C(O)R11Aryl and heteroaryl;
R7and R8Are the same OR different and are each independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, C (O) OR10Aryl and heteroaryl;
or R7And R8Together form a cycloalkyl or heterocyclyl group;
R9is alkyl, optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkoxy, hydroxy, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R10selected from the group consisting of hydrogen atoms, alkyl groups, haloalkyl groups, hydroxyalkyl groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups;
R11selected from the group consisting of hydrogen atoms, alkyl groups, haloalkyl groups, hydroxyalkyl groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups;
n is an integer of 1 to 6;
r is 0, 1,2 or 3;
s is 0, 1,2, 3 or 4; and is
q is 0, 1,2, 3 or 4.
2. The compound of claim 1, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein G is1Is an O atom.
3. The compound according to claim 1 or 2, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein R is2aIs C1-6Alkyl, preferably methyl.
4. A compound according to any one of claims 1 to 3, or a tautomer thereofA isomer, cis or trans, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein R4And R5Is a hydrogen atom.
5. The compound according to any one of claims 1 to 4, which is a compound represented by the general formula (II), or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,
wherein:
ring A, X1、X2、R1、R2、R3S, r and q are as defined in claim 1.
6. The compound of any one of claims 1 to 5, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein X is1And X2Are the same or different and are each independently selected from the group consisting of a hydrogen atom, -CH2-R0and-C (═ O) O (CQ)1Q2)n-R0(ii) a Provided that X is1And X2Not being hydrogen atoms at the same time; r0、Q1、Q2And n is as defined in claim 1.
7. The compound of any one of claims 1 to 5, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein X is1And X2Are the same or different and are each independently selected from the group consisting of a hydrogen atom, -CH2OC(=O)CH3、-CH2OC(=O)OCH3、-CH2OC(=O)NHCH3、-CH2OP(=O)(OH)2、-CH2OP(=O)(OH)OP(=O)(OH)2、-CH2OP(=O)(OQ4)2、-C(=O)OCH2OC(=O)C(CH3)3、-C(=O)OCH2OP(=O)(OH)2、-C(=O)OCH2CH2OP(=O)(OH)2、-C(=O)OCH2OC(=O)CH=CHCOOH、 Provided that X is1And X2Not being hydrogen atoms at the same time; q4As defined in claim 1.
8. The compound of claim 1, which is a compound of formula (III) or formula (IV), or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,
wherein:
L1and L2Are the same or different and are each independently selected from-CH2-、-C(=O)O(CQ1Q2)n-and-C (═ O) S (CQ)1Q2)n-; preferably, L1And L2Are the same or different and are each independently-CH2-;
RaAnd RbAre identical or different and are each independently selected from the group consisting of-OP (═ O) (OH)2、-OP(=O)(OH)-OP(=O)(OH)2、-OC(=O)Q3、-OC(=O)OQ3、-OC(=O)NHQ3、-OP(=O)(OQ4)2、-O-C(=O)(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)(CQ1Q2)n-Cy-OP(=O)(OH)2,-OC(=O)CH=CHC(=O)OH、-O-C(=O)-O-(CQ1Q2)n-OP(=O)(OH)2、-O-C(=O)-NH-(CQ1Q2)n-OP(=O)(OH)2、-OC(=O)CH(Q5)-NQ6Q7and-NQ6Q7(ii) a preferably-OP (═ O) (OH)2。
Ring A, R1、R2、R3、Cy、Q1~Q7S, r, q and n are as defined in claim 1.
9. The compound of any one of claims 1 to 8, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein ring a is a 5-or 6-membered heteroaryl; pyridyl, pyridazinyl and pyrimidinyl are preferred.
11. The compound according to any one of claims 1 to 10, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein R is1Is haloalkyl or haloalkoxy; preferably a halogen atom1-6Alkyl or halo C1-6An alkoxy group.
12. The compound according to any one of claims 1 to 11, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein R is2And R3Is a hydrogen atom.
14. A compound of formula (IIIA) or (IVA):
or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,
wherein:
Rwis-SCH3Or an iodine atom;
ring a is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
L1and L2Are the same or different and are each independently selected from-CH2-、-C(=O)O(CQ1Q2)n-and-C (═ O) S (CQ)1Q2)n-; preferably, L1And L2Are the same or different and are each independently-CH2-;
Q1And Q2Are identical or different and are each independently selected from the group consisting of a hydrogen atom, an alkyl group and-C (═ O) R9Wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R9is alkyl, optionally substituted with one or more substituents selected from the group consisting of alkoxy, halo, haloalkoxy, hydroxy, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R1the same or different, and each is independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroarylIs substituted with one or more substituents of (1);
R2the same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R3the same or different, and each is independently selected from the group consisting of hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
n is an integer of 1 to 6;
r is 0, 1,2 or 3;
s is 0, 1,2, 3 or 4; and is
q is 0, 1,2, 3 or 4.
16. a process for preparing a compound of formula (III) or formula (IV) according to claim 8, or a tautomer, cis or trans isomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, comprising:
a compound of the formula (IIIA) and Ra-H reaction to give a compound of general formula (III);
compounds of the general formula (IVA) and Rb-H reaction to give a compound of general formula (IV);
wherein:
Rwis-SCH3;
Ring A, R1、R2、R3、L1、L2、Ra、RbS, r and q are as defined in claim 8.
17. A pharmaceutical composition comprising a compound of general formula (I) according to any one of claims 1 to 13, or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
18. Use of a compound of general formula (I) according to any one of claims 1 to 13 or a tautomer, cis or trans isomer, meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 17, for the manufacture of a medicament for the inhibition of RAF.
19. Use of a compound of general formula (I) according to any one of claims 1 to 13 or a tautomer, cis or trans isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition according to claim 17, for the manufacture of a medicament for the treatment of a RAF mediated disease or disorder; preferably, the RAF mediated disease or disorder is cancer.
20. The use of claim 19, wherein the cancer is selected from the group consisting of lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, mesothelioma, cervical cancer, colon cancer, rectal cancer, stomach cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, bone cancer, kidney cancer, bladder cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, glioma, glioblastoma, head and neck cancer, and myeloma; lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdomyosarcoma, synovial sarcoma, and mesothelioma are preferred.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020102084702 | 2020-03-23 | ||
CN202010208470 | 2020-03-23 | ||
CN2021101849519 | 2021-02-10 | ||
CN202110184951 | 2021-02-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113429440A true CN113429440A (en) | 2021-09-24 |
CN113429440B CN113429440B (en) | 2023-05-12 |
Family
ID=77752896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110305777.9A Active CN113429440B (en) | 2020-03-23 | 2021-03-23 | Prodrug of spiro compound, preparation method and application thereof in medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113429440B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113264945A (en) * | 2020-02-17 | 2021-08-17 | 江苏恒瑞医药股份有限公司 | Spiro derivative, preparation method and medical application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014207648A1 (en) * | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
CN108699065A (en) * | 2015-12-18 | 2018-10-23 | 诺华股份有限公司 | Tricyclic compounds and composition as kinase inhibitor |
CN109963845A (en) * | 2017-05-23 | 2019-07-02 | 江苏恒瑞医药股份有限公司 | Loop coil carboxamides derivatives, preparation method and its application in medicine |
-
2021
- 2021-03-23 CN CN202110305777.9A patent/CN113429440B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014207648A1 (en) * | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
CN108699065A (en) * | 2015-12-18 | 2018-10-23 | 诺华股份有限公司 | Tricyclic compounds and composition as kinase inhibitor |
CN109963845A (en) * | 2017-05-23 | 2019-07-02 | 江苏恒瑞医药股份有限公司 | Loop coil carboxamides derivatives, preparation method and its application in medicine |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113264945A (en) * | 2020-02-17 | 2021-08-17 | 江苏恒瑞医药股份有限公司 | Spiro derivative, preparation method and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113429440B (en) | 2023-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7211959B2 (en) | Amide derivative inhibitor and its production method and use | |
WO2020156311A1 (en) | Pyridazine derivative inhibitor, and preparation method and application thereof | |
CN111107848B (en) | Pharmaceutical composition containing amide derivatives, and preparation method and application thereof | |
TW202115076A (en) | Pyrimidine five-membered nitrogen heterocyclic derivatives, a preparation method thereof and pharmaceutical use thereof | |
CN107033097B (en) | Oxadiazole derivative, preparation method and medical application thereof | |
CN106187915A (en) | There is inhibitor of ALK Yu EGFR double activity and its preparation method and application | |
KR20210150491A (en) | Phosphatidylinositol 3-kinase inhibitor | |
TW202016120A (en) | Tricyclic derivatives inhibitor, preparation method, and applications thereof | |
RU2742770C1 (en) | Indole derivative and formamide, method for production thereof and use in medicine | |
US20210355107A1 (en) | Multi-substituted pyridone derivatives and medical use thereof | |
WO2022105771A1 (en) | Nitrogen-containing heterocyclic derivative, and preparation method therefor and medical application thereof | |
TW201917129A (en) | Triacyclic derivatives containing pyrazole, their preparation methods and applications thereof | |
CN117597341A (en) | Sulfonamide derivative, preparation method and application thereof in medicine | |
WO2022089389A1 (en) | Heterocyclic compound, preparation method therefor, pharmaceutical composition thereof and application thereof | |
CN113429440B (en) | Prodrug of spiro compound, preparation method and application thereof in medicine | |
EP4039674A1 (en) | Sulfo-substituted biaryl compound or salt thereof, preparation method therefor, and use thereof | |
CN109535132B (en) | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | |
TW202325298A (en) | A nitrogen-containing tetracyclic compound, a preparation method and medical use thereof | |
CN112996783B (en) | 2-aminopyrimidine derivatives, preparation method and application thereof in medicines | |
TW201817726A (en) | 3,4-dipyridinyl pyrazole derivatives, a preparation method thereof and pharmaceutical use thereof | |
CN113912608B (en) | Pyrimidopyrimidinone derivatives, preparation method thereof and application thereof in medicines | |
CN110964034B (en) | Pyrimidothiophene derivative, preparation method and medical application thereof | |
WO2022166810A1 (en) | Fused azatricyclic derivative, preparation method therefor, and application thereof in medicine | |
WO2022161447A1 (en) | Dicarboxamide compound, preparation method therefor, and pharmaceutical use thereof | |
WO2024046420A1 (en) | Fused bicyclic compound, and preparation method therefor and use thereof in medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |